Our Pricing

Best Prescription Weight Loss Injection UK: Expert Comparison Guide

Finding the best prescription weight loss injection UK pharmacies offer requires understanding how each treatment works and which suits your clinical profile. At Cured Pharmacy, our UK-registered prescribers assess your medical history to recommend the most appropriate GLP-1 or dual-agonist therapy, with transparent pricing from £135.00 and discreet delivery across the UK.

How GLP-1 and Dual-Agonist Weight Loss Injections Work

Prescription weight loss injections in the UK fall into two categories: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity [1]. Medications like Wegovy and Saxenda work by mimicking this single pathway, helping patients feel fuller for longer and reducing caloric intake.

Mounjaro represents the newer dual-agonist approach, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously [2]. This dual mechanism produces enhanced metabolic effects compared to GLP-1-only treatments. In the SURMOUNT-1 trial, participants receiving the highest tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks, compared to 14.9% with semaglutide 2.4mg in head-to-head studies [2][3].

All prescription weight loss injections require gradual dose escalation over several weeks to minimise gastrointestinal side effects. Your UK prescriber will determine your starting dose and titration schedule based on your tolerance, weight loss goals, and any concurrent medical conditions such as type 2 diabetes.

Mounjaro (Tirzepatide): The Dual-Agonist Option

Mounjaro is the first and only dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [2]. Available as a once-weekly subcutaneous injection in pre-filled KwikPen devices, it offers five maintenance doses (2.5mg, 5mg, 7.5mg, 10mg, and 15mg) to allow personalised titration.

Clinical trial data demonstrates superior efficacy compared to single-pathway treatments. The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, showing average weight reductions of 15% (5mg), 19.5% (10mg), and 22.5% (15mg) at 72 weeks [2]. Participants also experienced significant improvements in cardiovascular risk markers, including blood pressure, lipid profiles, and inflammatory markers.

At Cured Pharmacy, Mounjaro starts from £135.00 following clinical assessment by a UK prescriber. The dual-agonist mechanism may offer advantages for patients who have not achieved sufficient weight loss with GLP-1-only treatments, though individual response varies and requires ongoing monitoring.

Who May Benefit from Mounjaro

Mounjaro is typically prescribed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [2]. Your UK prescriber will assess whether the dual-agonist mechanism is appropriate based on your medical history, previous treatment response, and clinical goals. Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 cannot use tirzepatide.

Wegovy (Semaglutide): The Established GLP-1 Injection

Wegovy contains semaglutide 2.4mg, a once-weekly GLP-1 receptor agonist licensed in the UK since 2022 for chronic weight management [3]. It shares the same active ingredient as Ozempic (used for type 2 diabetes) but at a higher maintenance dose specifically approved for weight loss.

The STEP clinical trial programme demonstrated robust efficacy across diverse patient populations. In STEP 1, participants without diabetes achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [3]. Secondary endpoints showed improvements in waist circumference, glycaemic control, and physical functioning scores.

Wegovy is administered via pre-filled FlexTouch pens, starting at 0.25mg weekly and escalating over 16 weeks to the 2.4mg maintenance dose. This gradual titration minimises common gastrointestinal side effects such as nausea, vomiting, and diarrhoea, which typically resolve within the first 4-8 weeks of treatment [3].

Wegovy vs Mounjaro: Clinical Considerations

While both medications are highly effective, indirect comparisons suggest tirzepatide produces greater absolute weight loss on average [2][3]. However, individual response varies considerably, and some patients achieve excellent results with semaglutide while experiencing fewer side effects. Your UK prescriber will consider factors including your previous treatment history, tolerance profile, concurrent medications, and cost when recommending the most suitable option. Both treatments require long-term commitment and lifestyle modification for sustained results.

Saxenda (Liraglutide): The Daily Injection Alternative

Saxenda contains liraglutide 3mg, a GLP-1 receptor agonist administered once daily via subcutaneous injection [4]. Unlike the weekly injections of Mounjaro and Wegovy, Saxenda requires daily dosing, which some patients find less convenient but others prefer for more granular dose control.

The SCALE clinical trial programme evaluated liraglutide 3mg in over 5,000 participants across multiple studies. Average weight loss at 56 weeks ranged from 8% to 9.2% of baseline body weight, with 63.2% of participants losing at least 5% of their body weight compared to 27.1% on placebo [4]. While these results are clinically meaningful, they are generally lower than those observed with higher-dose semaglutide or tirzepatide.

Saxenda may be particularly suitable for patients who prefer daily dosing, have contraindications to higher-potency GLP-1 treatments, or are taking concurrent medications requiring careful monitoring. The daily injection schedule allows for more flexible dose adjustments if side effects occur. Starting from £135.00 at Cured Pharmacy, it represents a lower entry point for patients beginning GLP-1 therapy, subject to prescriber approval.

Comparing Side Effects and Tolerability Across Weight Loss Injections

All GLP-1 and dual-agonist weight loss injections share a similar side effect profile, with gastrointestinal symptoms being most common [1][2][3]. Nausea affects 20-44% of patients depending on the medication and dose, typically peaking during dose escalation and resolving within 4-8 weeks. Vomiting, diarrhoea, constipation, and abdominal discomfort occur less frequently but can be dose-limiting in some individuals.

Tirzepatide appears to have a slightly higher incidence of gastrointestinal side effects compared to semaglutide, though most cases are mild to moderate in severity [2]. Liraglutide's daily dosing may produce more consistent but lower-intensity symptoms compared to the weekly injections. Serious adverse events are rare but include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications).

Your UK prescriber will review your complete medical history to identify any contraindications, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Regular monitoring during treatment ensures early detection of any adverse effects and allows dose adjustment if needed.

Managing Common Side Effects

Most gastrointestinal side effects can be minimised through gradual dose titration, eating smaller meals, avoiding high-fat foods, and staying well-hydrated. If nausea persists beyond the first month, your prescriber may slow the titration schedule or recommend anti-emetic medications. Injection site reactions (redness, itching, bruising) occur in fewer than 5% of patients and typically resolve without intervention. Always report persistent or severe side effects to your healthcare provider promptly.

Choosing the Best Prescription Weight Loss Injection for Your Needs

Selecting the best prescription weight loss injection UK patients can access depends on multiple factors beyond efficacy data alone. Your BMI, weight loss goals, previous treatment history, concurrent medical conditions, lifestyle preferences, and budget all influence the optimal choice. A patient with type 2 diabetes and significant obesity may benefit most from tirzepatide's dual mechanism, while someone seeking a lower-cost entry point might start with liraglutide.

Dosing frequency matters for long-term adherence. Weekly injections (Mounjaro, Wegovy) offer greater convenience and may improve compliance compared to daily injections (Saxenda), though individual preferences vary. Some patients prefer the flexibility of daily dosing to manage side effects more precisely, while others value the simplicity of a once-weekly schedule.

At Cured Pharmacy, our UK-registered prescribers conduct comprehensive clinical assessments to recommend the most appropriate treatment based on your individual profile. The online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. All medications are genuine UK-licensed products dispensed by our GPhC-registered pharmacy, with discreet packaging and next-day delivery options available across the UK.

Starting Your Weight Loss Journey

Prescription weight loss injections are most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating significant weight loss all included lifestyle intervention components [2][3][4]. Your prescriber may recommend working with a dietitian, setting realistic physical activity goals, and monitoring your progress through regular weigh-ins and body composition assessments. Treatment duration varies, but most patients require at least 12 months to achieve and consolidate meaningful weight loss, with some continuing therapy long-term to maintain results.

Scientific References

1. Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., Wilding, J. P., & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.